Regenxbio closes strategic partnership with Nippon Shinyaku for MPS diseases: Rockville, Maryland Wednesday, March 5, 2025, 14:00 Hrs [IST] Regenxbio Inc., a leading clinical-stag ...

Several rare disease patient populations received their first-ever FDA-approved drug since Rare Disease Day last year, ...

Experts at BJMC and SGH are sequencing Chikungunya virus to investigate mutations linked to severe cases and outbreaks in ...

It has been five years since the World Health Organisation (WHO) declared COVID-19 a pandemic in March 2020 a decision that ...

Scientists at the National Institute of Virology NIV have detected a troubling mutation in the Zika virus strain that spread ...

Built like a juggernaut, with a solid heart of gold. Love him so much,' Shivon Zilis wrote in her announcement.

REGENXBIO Inc.  today announced the closing of its previously announced strategic partnership with Nippon Shinyaku. Under the terms of the agreement, REGENXBIO and Nippon Shinyaku will develop and ...

Solid Biosciences reported recent positive data in developing their gene therapy candidate SGT-003. The phase 1/2 INSPIRE ...

Methods: We reviewed the clinical data of three Chinese children with INSR-related insulin resistance syndrome from two unrelated kindreds ... A Flag-tagged INSR expression vector (wild or mutant type ...

This useful study presents findings on the developmental roles of Nup107, a key nucleoporin, in regulating the larval-to-pupal transition in Drosophila melanogaster through its involvement in ecdysone ...

Lentiviral Vectors Market Size 2025 Lentiviral Vectors Market is estimated to be valued at US$ 292 million in 2023 and is expected to exhib ...

WHO highlights encephalitis as a public health priority, urging a national strategy to tackle the disease effectively.